with Rhofade added contribution and the impact of $10 m cost reduction =+ve EBITDA 20 M fy24
500 m MC
Ann: Mayne Pharma provides update on 1Q FY24 trading and outlook, page-22
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.52 |
Change
0.000(0.00%) |
Mkt cap ! $384.5M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 400 | $4.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.30 | 8 | 1 |
View Market Depth
| Last trade - 09.52am 18/09/2024 (20 minute delay) ? |
| MYX (ASX) Chart |
Day chart unavailable